Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade

Cho,Hyun‑Ji; Ahn,Kwang‑Chul; Choi,Jae Yeon; Hwang,Sang‑Gu; Kim,Wun‑Jae; Um,Hong‑Duck; Park,Jong Kuk

doi:10.3892/ijo.2015.2831

Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade

Authors:
- Hyun‑Ji Cho
- Kwang‑Chul Ahn
- Jae Yeon Choi
- Sang‑Gu Hwang
- Wun‑Jae Kim
- Hong‑Duck Um
- Jong Kuk Park
View Affiliations

Affiliations: Department of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul 139‑706, Republic of Korea, Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 361‑763, Republic of Korea
Published online on: January 9, 2015 https://doi.org/10.3892/ijo.2015.2831
Pages: 1149-1158

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To improve radiation therapy, the development of effective radiosensitizer is required. Fifty percent inhibitory concentration (IC50) values of 3',4',5',7'‑tetrahydroxyflavone (luteolin) against NCI‑H460 and ‑H1299 non‑small cell lung cancer (NSCLC) cells were determined using 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT) assays. Radiosensitizing activity was assessed in vitro by treating cells with luteolin prior to irradiation of γ‑ionizing radiation (IR), and performing cell count and clonogenic assays. Cell signaling pathways involved in the radiosensitizing effects of luteolin were examined using propidium iodide (PI) uptake, reactive oxygen species (ROS) detection and immunoblot assays, with or without specific chemical inhibitors. Apoptotic cell death was confirmed by PI uptake and immunoblot assays. In vivo radiosensitizing activity was tested using an NCI‑H460 cell xenograft model in nude mice. Tumor size was measured and apoptosis was determined with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay in animals in four treatment groups: mock‑treated control, luteolin only, IR only, and luteolin plus IR. Treatment with luteolin or IR induced NSCLC cell death in vitro, but the combination of luteolin pre‑treatment and IR was more effective than either agent alone, yielding dose enhancement ratios (DERs) of 1.22 and 1.35 for NCI‑H460 and ‑H1299 cells, respectively. Combined treatment with luteolin and IR enhanced apoptotic cell death in association with downregulation of B‑cell lymphoma 2 (Bcl‑2) and activation of caspase‑3, ‑8, and ‑9; it also induced phosphorylation of p38 mitogen‑activated protein kinase (MAPK) and ROS accumulation. Inhibition of p38 MAPK decreased ROS production, and inhibition of either p38 MAPK or ROS production attenuated apoptotic cell death and activation of caspase‑8 and ‑9. In a xenograft model, tumor growth was delayed by 21.8 days in the luteolin/IR combination group compared with controls, and apoptotic cell death was increased. The enhancement factor of the luteolin and IR combination was 1.83. Collectively, these findings indicate that luteolin acts as a radiosensitizer by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kim JS, Amorino GP, Pyo H, Cao Q, Price JO and Choy H: The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys. 51:525–534. 2001. View Article : Google Scholar : PubMed/NCBI
3	Palayoor ST, Bump EA, Calderwood SK, Bartol S and Coleman CN: Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res. 4:763–771. 1998.PubMed/NCBI
4	Dicker AP, Williams TL and Grant DS: Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol. 24:438–442. 2001. View Article : Google Scholar : PubMed/NCBI
5	Kim KY, Seol JY, Jeon GA and Nam MJ: The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cells. Cancer Lett. 189:157–166. 2003. View Article : Google Scholar
6	Zhu AX and Willett CG: Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol. 13:454–468. 2003. View Article : Google Scholar : PubMed/NCBI
7	Jones PD, de Lorimier LP, Kitchell BE and Losonsky JM: Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc. 39:463–467. 2003. View Article : Google Scholar : PubMed/NCBI
8	Begg AC, Stewart FA and Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
9	Mitsudomi T, Suda K and Yatabe Y: Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 10:235–244. 2013. View Article : Google Scholar : PubMed/NCBI
10	Moding EJ, Kastan MB and Kirsch DG: Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov. 12:526–542. 2013. View Article : Google Scholar : PubMed/NCBI
11	Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multi-disciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 8:381–385. 2011. View Article : Google Scholar : PubMed/NCBI
12	Swinney DC and Anthony J: How were new medicines discovered? Nat Rev Drug Discov. 10:507–519. 2011. View Article : Google Scholar : PubMed/NCBI
13	Rask-Andersen M, Almén MS and Schiöth HB: Trends in the exploitation of novel drug targets. Nat Rev Drug Discov. 10:579–590. 2011. View Article : Google Scholar : PubMed/NCBI
14	Seelinger G, Merfort I, Wölfle U and Schempp CM: Anti-carcinogenic effects of the flavonoid luteolin. Molecules. 13:2628–2651. 2008. View Article : Google Scholar : PubMed/NCBI
15	Lin Y, Shi R, Wang X and Shen HM: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
16	Albert JM, Cao C, Kim KW, et al: Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 13:3033–3042. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kim EM, Yang HS, Kang SW, Ho JN, Lee SB and Um HD: Amplification of the gamma-irradiation-induced cell death pathway by reactive oxygen species in human U937 cells. Cell Signal. 20:916–924. 2008. View Article : Google Scholar : PubMed/NCBI
18	Leung HW, Kuo CL, Yang WH, Lin CH and Lee HZ: Antioxidant enzymes activity involvement in luteolin-induced human lung squamous carcinoma CH27 cell apoptosis. Eur J Pharmacol. 534:12–18. 2006. View Article : Google Scholar : PubMed/NCBI
19	Rebucci M and Michiels C: Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI
20	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
21	Park JK, Jung HY, Park SH, Kang SY, Yi MR, Um HD and Hong SH: Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys. 70:1552–1560. 2008. View Article : Google Scholar : PubMed/NCBI
22	Prise KM, Schettino G, Folkard M and Held KD: New insights on cell death from radiation exposure. Lancet Oncol. 6:520–528. 2005. View Article : Google Scholar : PubMed/NCBI
23	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
24	Katz D, Ito E and Liu FF: On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys. 73:988–996. 2009. View Article : Google Scholar : PubMed/NCBI
25	Munshi A and Ramesh R: Mitogen-activated protein kinases and their role in radiation response. Genes Cancer. 4:401–408. 2013. View Article : Google Scholar : PubMed/NCBI
26	Park JK, Chung YM, Kim BG, Yoo YA, Yang BS, Kim JS and Yoo YD: N′-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells. Mol Cancer Ther. 3:403–407. 2004.PubMed/NCBI
27	Caputo F, Vegliante R and Ghibelli L: Redox modulation of the DNA damage response. Biochem Pharmacol. 84:1292–1306. 2012. View Article : Google Scholar : PubMed/NCBI
28	Park MT, Kim MJ, Kang YH, et al: Phytosphingosine in combination with ionizing radiation enhances apoptotic cell death in radiation-resistant cancer cells through ROS-dependent and -independent AIF release. Blood. 105:1724–1733. 2005. View Article : Google Scholar
29	Lee YJ, Lee DH, Cho CK, et al: HSP25 inhibits radiation-induced apoptosis through reduction of PKCdelta-mediated ROS production. Oncogene. 24:3715–3725. 2005. View Article : Google Scholar : PubMed/NCBI
30	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ju W, Wang X, Shi H, Chen W, Belinsky SA and Lin Y: A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol. 71:1381–1388. 2007. View Article : Google Scholar : PubMed/NCBI